Switching Between CGRP Antibody Classes May Help Migraine Patients Who Don't Respond to Their First CGRP Drug
In 53 migraine patients in the UAE who switched between CGRP antibody classes (ligand-targeting to receptor-targeting or vice versa) due to lack of efficacy or poor tolerability, both switch directions showed some clinical improvement with no new safety concerns.
Quick Facts
What This Study Found
53 migraine patients switched between CGRP mAb classes (CGRP/R to CGRP/L or CGRP/L to CGRP/R). Both switch cohorts showed some clinical improvements. Safety was maintained — adverse events from the first antibody did not recur or worsen after switching classes. Fremanezumab was not included due to UAE unavailability.
Key Numbers
53 patients switched between CGRP antibody classes. Studied in a UAE clinical setting.
How They Did This
Retrospective real-world study of 53 migraine patients at a UAE center who switched between CGRP mAb classes (eptinezumab, erenumab, galcanezumab) due to lack of efficacy or poor tolerability. Efficacy assessed by clinical improvement measures. Safety evaluated by adverse event monitoring.
Why This Research Matters
Up to 30-50% of migraine patients don't respond adequately to their first CGRP antibody. Clinicians face uncertainty about whether switching to a different CGRP antibody — particularly one from a different class — can help. This study provides early real-world evidence that class switching is both safe and potentially effective.
The Bigger Picture
As CGRP antibodies become standard migraine prevention therapy, managing non-responders is increasingly important. This study supports the hypothesis that failing one CGRP antibody doesn't mean CGRP biology is irrelevant — the difference between targeting the peptide versus its receptor may matter for individual patients.
What This Study Doesn't Tell Us
Small sample size (53 patients) limits statistical power. Retrospective design without a control group. No standardized outcome measures described. Single-center UAE study — population may not be representative. Fremanezumab excluded. Preliminary designation by the authors themselves.
Questions This Raises
- ?Are there predictive biomarkers for which patients will benefit from switching CGRP antibody classes versus trying a different preventive approach entirely?
- ?Does the direction of switch (ligand→receptor vs receptor→ligand) matter for outcomes?
- ?Would results differ with fremanezumab included as a switching option?
Trust & Context
- Key Stat:
- 53 patients switched classes Migraine patients who failed one CGRP antibody showed improvement when switched to a different class — suggesting the mechanism of CGRP targeting (peptide vs receptor) matters for individual response
- Evidence Grade:
- Rated preliminary: small retrospective study (53 patients) without standardized outcomes or control group. Provides initial real-world signal but needs larger prospective validation.
- Study Age:
- Published in 2024. Addresses a current clinical question as CGRP antibodies become widely used.
- Original Title:
- Effectiveness of Switching CGRP Monoclonal Antibodies in Non-Responder Patients in the UAE: A Retrospective Study.
- Published In:
- Neurology international, 16(1), 274-288 (2024)
- Authors:
- Suliman, Reem(3), Santos, Vanessa, Al Qaisi, Ibrahim(2), Aldaher, Batool, Al Fardan, Ahmed, Al Barrawy, Hajir, Bader, Yazan, Supena, Jonna Lyn, Alejandro, Kathrina, Alsaadi, Taoufik
- Database ID:
- RPEP-09342
Evidence Hierarchy
Frequently Asked Questions
If one CGRP migraine drug doesn't work, should I try another one?
This study suggests it's worth trying, especially if you switch to a different type. CGRP antibodies come in two classes: some target the CGRP molecule itself, others target the CGRP receptor. Patients who failed one type sometimes improved when switched to the other type. The switch appeared safe with no new side effects.
What's the difference between CGRP ligand and receptor antibodies?
CGRP (calcitonin gene-related peptide) triggers migraine through a specific receptor. Some antibodies (galcanezumab, eptinezumab) grab the CGRP molecule itself before it can reach the receptor. Others (erenumab) block the receptor directly. They achieve the same goal — stopping CGRP signaling — but through different mechanisms, which may explain why switching between them can work.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09342APA
Suliman, Reem; Santos, Vanessa; Al Qaisi, Ibrahim; Aldaher, Batool; Al Fardan, Ahmed; Al Barrawy, Hajir; Bader, Yazan; Supena, Jonna Lyn; Alejandro, Kathrina; Alsaadi, Taoufik. (2024). Effectiveness of Switching CGRP Monoclonal Antibodies in Non-Responder Patients in the UAE: A Retrospective Study.. Neurology international, 16(1), 274-288. https://doi.org/10.3390/neurolint16010019
MLA
Suliman, Reem, et al. "Effectiveness of Switching CGRP Monoclonal Antibodies in Non-Responder Patients in the UAE: A Retrospective Study.." Neurology international, 2024. https://doi.org/10.3390/neurolint16010019
RethinkPeptides
RethinkPeptides Research Database. "Effectiveness of Switching CGRP Monoclonal Antibodies in Non..." RPEP-09342. Retrieved from https://rethinkpeptides.com/research/suliman-2024-effectiveness-of-switching-cgrp
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.